简单的总是更好的吗? 在阿尔茨海默病中超越粉样蛋白假设的理由
1Department of Medicine, Faculty of Medicine and Health Sciences, Division of Neurology, Memory Clinic and Research Centre on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada.
Journal of Alzheimer's disease : JAD
|July 12, 2024
概括
阿尔茨海默病的研究一直专注于粉样蛋白假设. 然而,许多替代单因子假设表明,阿尔茨海默病是一种复杂的多因子疾病,需要更广泛的解释模型.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 老年学是一门学科.
背景情况:
- 几十年来,阿尔茨海默病 (AD) 研究一直受到粉样蛋白假设的严重影响.
- 基于粉样蛋白的疗法的有限成功促使人们对替代的病因因素进行调查.
- 许多单因素假设 (血管,代谢,传染,炎症) 存在于AD.
研究的目的:
- 对阿尔茨海默病的各种病因学假设进行审查和清单.
- 为了突出阿尔茨海默病的多因素性质,超越了粉样蛋白假设.
- 鼓励开发对AD的全面解释模型.
主要方法:
- 文献综述和对阿尔茨海默病现有的病因学假设的综合.
- 对单因素假设与多因素观点进行比较分析.
- 为了解AD病因学的概念框架的开发.
主要成果:
- 粉样蛋白假设一直主导着阿尔茨海默病的研究,但治疗结果有限.
- 已经出现了各种各样的替代单因素假设,表明复杂性.
- 假设的扩散表明,阿尔茨海默病可能是一种多因素性疾病.
结论:
- 阿尔茨海默病可能是一个复杂的,多因素的情况.
- 未来的研究应该整合多个因素,以全面了解AD.
- 开发多因素模型对于推动AD研究和治疗至关重要.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉样蛋白假设是什么?生物标志物 生物标志物痴呆症 痴呆症是一种痴呆症.诊断标准 诊断标准 诊断标准 诊断标准病因学假设 病因学假设有多种多重的病因.神经病理学神经病理学更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
